{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:04Z","timestamp":1790797084277,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The relative effects of monoclonal antibody against calcitonin gene-related peptide (CGRP) or its receptor for adult migraine patients with prior treatment failure remains uncertain. Therefore, this study systematically assessed the comparative effectiveness of different CGRP binding monoclonal antibodies (mAbs) for these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Several online databases including Ovid MEDILNE, Ovid EMBASE, Cochrane Library, and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> were systematically searched from inception to June 15, 2022. We included randomized clinical trials (RCT) of adult migraine patients with previous treatment failure that assessed any CGRP monoclonal antibody. The primary efficacy outcome was change in monthly migraine days (MMDs), and the primary safety outcome was treatment-emergent adverse events (TEAEs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, seven studies totaling 3, 052 patients were included. Three-node analysis showed that CGRP mAbs was superior to CGRP receptor mAbs in reducing MMDs (MD: -1.55, 95% CrI: \u2212\u20092.43 to \u2212\u20090.44) and improving at least 50% response rates (RR: 1.52, 95% CrI: 1.04 to 2.21). Nine-node analysis showed galcanezumab 240\u2009mg ranked first in reducing MMDs (MD -4.40, 95% CrI \u2212\u20097.60 to \u2212\u20091.19) and improving 50% response rates (RR: 4.18, 95% CrI: 2.63 to 6.67). Moreover, treatment with fremanezumab or eptinezumab 300\u2009mg provides a significant advantage over erenumab 140\u2009mg regarding an improved response rate of at least 50%. The analysis did not show difference in incidences of TEAEs and serious adverse events in any of the comparisons.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>It appears that CGRP mAbs, especially galcanezumab 240\u2009mg, monthly fremanezumab, and eptinezumab 300\u2009mg, seem to be the best choice for the treatment of migraine patients with previous treatment failures. This finding also calls for future research that examine the associations between these medications in migraine therapy among the same patient group to testify the present findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01472-2","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T23:02:44Z","timestamp":1662591764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Xing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingke","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"issue":"7","key":"1472_CR1","doi-asserted-by":"publisher","first-page":"Itc49","DOI":"10.7326\/AITC201704040","volume":"166","author":"EA MacGregor","year":"2017","unstructured":"MacGregor EA (2017) Migraine. Ann Intern Med 166(7):Itc49\u2013itc64","journal-title":"Ann Intern Med"},{"issue":"16","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1177\/0333102411425866","volume":"31","author":"C Gaul","year":"2011","unstructured":"Gaul C, Finken J, Biermann J, Mostardt S, Diener HC, M\u00fcller O et al (2011) Treatment costs and indirect costs of cluster headache: a health economics analysis. Cephalalgia 31(16):1664\u20131672","journal-title":"Cephalalgia"},{"issue":"2","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.12755","volume":"56","author":"A Messali","year":"2016","unstructured":"Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF et al (2016) Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache 56(2):306\u2013322","journal-title":"Headache"},{"issue":"1","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/17425255.2018.1416097","volume":"14","author":"A Gonz\u00e1lez-Hern\u00e1ndez","year":"2018","unstructured":"Gonz\u00e1lez-Hern\u00e1ndez A, Marichal-Cancino BA, MaassenVanDenBrink A, Villal\u00f3n CM (2018) Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol 14(1):25\u201341","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"1472_CR5","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/head.13202","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK (2017) A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache 57(10):1532\u20131544","journal-title":"Headache"},{"issue":"1","key":"1472_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC et al (2018) My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain 19(1):115","journal-title":"J Headache Pain"},{"issue":"2","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s40122-021-00331-3","volume":"10","author":"P Pozo-Rosich","year":"2021","unstructured":"Pozo-Rosich P, Lucas C, Watson DPB, Gaul C, Ramsden E, Ritter S et al (2021) Burden of migraine in patients with preventive treatment failure attending European headache specialist centers: real-world evidence from the BECOME study. Pain Ther 10(2):1691\u20131708","journal-title":"Pain Ther"},{"issue":"12","key":"1472_CR8","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/14712598.2019.1671350","volume":"19","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli B, Neeb L, Reuter U (2019) Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 19(12):1307\u20131317","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"1472_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/WCO.0000000000000548","volume":"31","author":"K Paemeleire","year":"2018","unstructured":"Paemeleire K, MaassenVanDenBrink A (2018) Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Curr Opin Neurol 31(3):274\u2013280","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"1472_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0333102417736900","volume":"39","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L, Warfvinge K (2019) Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia 39(3):366\u2013373","journal-title":"Cephalalgia"},{"issue":"19","key":"1472_CR11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"key":"1472_CR12","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.2147\/JPR.S287781","volume":"13","author":"M Shibata","year":"2020","unstructured":"Shibata M, Nakamura T, Ozeki A, Ueda K, Nichols RM (2020) Migraine-specific quality-of-life questionnaire (MSQ) version 2.1 score improvement in Japanese patients with episodic migraine by Galcanezumab treatment: Japan phase 2 study. J Pain Res 13:3531\u20133538","journal-title":"J Pain Res"},{"issue":"9","key":"1472_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"11","key":"1472_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"1472_CR15","doi-asserted-by":"crossref","unstructured":"(2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33(9):629\u2013808","DOI":"10.1177\/0333102413485658"},{"key":"1472_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"4","key":"1472_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401\u2013406","journal-title":"J Clin Epidemiol"},{"key":"1472_CR18","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (2019) Cochrane handbook for systematic reviews of interventions. New Jersey: Wiley","DOI":"10.1002\/9781119536604"},{"issue":"7","key":"1472_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597\u2013607","journal-title":"Lancet Neurol"},{"issue":"10161","key":"1472_CR20","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280\u20132287","journal-title":"Lancet"},{"issue":"7","key":"1472_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/0333102419835459","volume":"39","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F et al (2019) Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 39(7):817\u2013826","journal-title":"Cephalalgia"},{"issue":"1","key":"1472_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-021-01313-8","volume":"22","author":"K Hirata","year":"2021","unstructured":"Hirata K, Sakai F, Takeshima T, Imai N, Matsumori Y, Yoshida R et al (2021) Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial. J Headache Pain 22(1):110","journal-title":"J Headache Pain"},{"issue":"10203","key":"1472_CR23","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040","journal-title":"Lancet"},{"issue":"3","key":"1472_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/ene.14102","volume":"27","author":"J Ailani","year":"2020","unstructured":"Ailani J, Pearlman E, Zhang Q, Nagy AJ, Schuh K, Aurora SK (2020) Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies. Eur J Neurol 27(3):542\u2013549","journal-title":"Eur J Neurol"},{"issue":"10","key":"1472_CR25","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim B-K, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825","journal-title":"Lancet Neurol"},{"issue":"1","key":"1472_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","volume":"20","author":"H Deng","year":"2020","unstructured":"Deng H, Li GG, Nie H, Feng YY, Guo GY, Guo WL et al (2020) Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. BMC Neurol 20(1):57","journal-title":"BMC Neurol"},{"key":"1472_CR27","doi-asserted-by":"publisher","first-page":"105900","DOI":"10.1016\/j.clineuro.2020.105900","volume":"195","author":"YW Alasad","year":"2020","unstructured":"Alasad YW, Asha MZ (2020) Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis. Clin Neurol Neurosurg 195:105900","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"1472_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2174\/1570159X19666210823104916","volume":"20","author":"Y Yang","year":"2022","unstructured":"Yang Y, Chen M, Wu D, Sun Y, Jiang F, Chen Z et al (2022) Optimal dose of Erenumab for preventive treatment of episodic migraine: a systematic review and Meta-analysis. Curr Neuropharmacol 20(2):460\u2013470","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"1472_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23(1):67","journal-title":"J Headache Pain"},{"issue":"1","key":"1472_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas D-D et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache and Pain 20(1):6\u201338","journal-title":"J Headache and Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01472-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01472-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01472-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T23:02:47Z","timestamp":1662591767000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01472-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01472-2","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"30 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical approval was not required for this type of study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declared that there was no any potential conflict of interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}